OVERSEA CHINESE BANKING Corp Ltd Invests $723,000 in IQVIA Holdings Inc. $IQV

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,743 shares of the medical research company’s stock, valued at approximately $723,000.

A number of other hedge funds have also made changes to their positions in IQV. Vanguard Group Inc. raised its holdings in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after buying an additional 159,899 shares during the period. BlackRock Inc. acquired a new stake in IQVIA in the second quarter valued at $2,811,292,000. Geode Capital Management LLC raised its stake in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares in the last quarter. Boston Partners raised its stake in IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after buying an additional 530,672 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. BMO Capital Markets raised their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.88.

Insider Activity at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is owned by company insiders.

IQVIA Stock Up 1.6%

Shares of IQVIA stock opened at $260.17 on Friday. The stock has a 50-day moving average price of $213.32 and a 200 day moving average price of $187.52. The company has a market cap of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.17 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $260.40.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has initiated a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.